German Rare Disease Diagnostics Firm CENTOGENE Moves Closer to Asia’s Frontlines With Taiwan HQ

CENTOGENE, a rare disease diagnostics company founded in Rostock, Germany in 2006, formally inaugurated its Asia-Pacific headquarters in Taoyuan’s Zhongli District today, positioning the move as part of a broader effort to expand genomic diagnostics, rare disease testing, and precision medicine collaboration across Asia. The opening ceremony brought together clinicians, genetic counselors, laboratory partners, patient advocates, and biotechnology stakeholders — a cross-section that reflected both the breadth of the company’s operational ambitions and the weight of the problem they are attempting to address.

A Disease Landscape That Has Long Been Undercounted

Rare diseases — defined in most regulatory frameworks as conditions affecting fewer than 1 in 10,000 people — are individually uncommon but collectively enormous in scope. Approximately 300 million people worldwide live with a rare disease, and an estimated 72% of those conditions are genetic in origin, according to EURORDIS-Rare Diseases Europe. The most persistent challenge in this field is not treatment access but something more fundamental: getting to a diagnosis at all.

Research published in the European Journal of Human Genetics in 2024 found that the average total diagnosis time for rare disease patients in Europe is 4.7 years, with 56% of respondents still undiagnosed more than six months after their first medical contact — and those figures may understate the challenge in Asia, where registries are less complete and genomic testing infrastructure is less evenly distributed. An analysis by the NHS Genomics Education Programme places the global average at 5.6 years. In some regions the wait is far longer: a study in Genome Medicine examining rare disease patients in the Middle East found diagnostic odysseys averaging six to eight years, attributed largely to limited access to genomic investigations.

The consequences extend well beyond clinical outcomes. Earlier research found that delayed diagnosis generates between USD 86,000 and USD 517,000 in avoidable costs per patient, encompassing both direct medical expenditures and productivity losses, while a broader analysis estimated the total economic burden of rare disease in the United States alone at nearly USD 1 trillion annually — figures that underscore why diagnostic efficiency has become a policy and commercial priority.

“Without a diagnosis, treatment and genetic counseling cannot proceed,” said Ruth Kuan-Ju Chen, CEO of the Taiwan Foundation for Rare Disorders, at the opening ceremony. “We have been sending specimens abroad since 2000, seeking overseas assistance, because every disease is so rare and so difficult.”

Taiwan as Regional Outlier — and Strategic Anchor

Taiwan’s position in the rare disease landscape distinguishes it from most of its regional neighbors. In 2000, the country enacted its Rare Disease and Orphan Drug Act, becoming the fifth nation in the world to introduce dedicated rare disease legislation, according to Taiwan’s Health Promotion Administration. The Act, which was shaped in significant part by advocacy from the Taiwan Foundation for Rare Disorders, covers financial subsidies, orphan drug market exclusivity, diagnostic network development, and mandatory insurance coverage of approved treatments — a scope researchers have described as exceeding those of both the American and European orphan drug acts.

That legislative infrastructure, combined with a dense network of academic medical centers and a biotech talent base that CENTOGENE APAC CEO Andy Chang cited explicitly at the opening, made Taiwan the preferred location for the regional headquarters over more commonly selected hubs elsewhere in Asia.

“The Asia-Pacific market is special because there are still many unresolved medical problems,” Chang said during his keynote address. “This market needs to be recognized, understood, and valued.”

Beyond strategic calculation, Chang described a more personal dimension: Taiwan is his hometown, and establishing the headquarters there — rather than following standard industry practice — carried, in his own words, “an even bigger meaning.”

The Genomics Infrastructure Gap — and a Market Responding

The backdrop to CENTOGENE’s entry is a rapidly expanding market that remains structurally uneven. According to a recent forecast, the global genomics market stood at USD 44.5 billion in 2024 and is projected to reach USD 85.1 billion by 2030 at a compound annual growth rate of 12.6%, with Asia-Pacific identified as the fastest-growing regional segment — driven by government genomic initiatives in China, Japan, and India, expanding healthcare infrastructure, and a large patient population with significant unmet needs in genetic disease.

Asia-Pacific currently holds approximately 24% of the global clinical genomics market, but its share is expected to grow disproportionately as sequencing costs continue to fall and reimbursement frameworks mature, according to a 2026 analysis by Coherent Market Insights.

Despite this trajectory, Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) — now widely used as first-tier diagnostic tools in European and North American clinical settings — have entered routine clinical practice unevenly across Asia-Pacific. Access barriers include cost, laboratory logistics, limited local bioinformatics interpretation capacity, and a shortage of trained genetic counselors. Cold-chain specimen shipping, required for many traditional sample types including fibroblasts and amniotic fluid, has compounded the challenge for patients in lower-income countries or rural settings.

Chen, who also serves as a director of the Asia Pacific Alliance for Rare Disease Organizations, described the practical difficulty that preceded newer sequencing workflows: “We had to draw blood and have it reach Germany within a certain timeframe. Sometimes we sent amniotic fluid, sometimes fibroblasts. Just packaging those specimens almost made us faint.”

Evidence that closing these gaps produces meaningful clinical change is accumulating. A 2024 multicenter study published in Pediatric Critical Care Medicine found that rapid whole-genome sequencing achieved a molecular diagnosis in 59% of critically ill pediatric patients tested across four institutions, with changes in clinical management occurring in 80% of diagnosed patients and preliminary results returned in a median of three days. Comparable data from the Rady Children’s Institute for Genomic Medicine has demonstrated diagnostic rates of 57% and management changes in up to 70% of infants who received a diagnosis — figures that have accelerated advocacy for broader genomic testing access in markets historically reliant on slower, sequential single-gene testing approaches.

Data Platforms Become the Competitive Frontier

Speakers throughout the ceremony returned to a theme that goes beyond sequencing capability: the strategic importance of reference databases large enough to interpret results for diseases that may affect only a handful of patients globally.

CENTOGENE enters the Asia-Pacific market with a dataset accumulated over two decades. Its BioDatabank contains multiomic and clinical data from more than one million individuals across 120 countries, cataloguing over 70 million unique variants and 140,000 clinically curated variants. That scale is particularly relevant in rare disease diagnostics, where distinguishing a disease-causing mutation from a benign variant requires population-level frequency data that is simply unavailable for conditions affecting one in several hundred thousand people.

This reflects a wider structural shift in the genomics sector. Competitive differentiation is moving away from sequencing hardware alone and toward interpretation layers — including variant databases, phenotype correlation systems, and AI-supported clinical decision tools. The company’s CentoDx® platform, described in its materials as an end-to-end genomic knowledge management system combining advanced bioinformatics, automation, and expert-reviewed algorithms, is the operational expression of that strategy.

Pharmaceutical partnerships represent a separate but related dimension of CENTOGENE’s positioning. The company’s pharma solutions division — covering patient identification and stratification, clinical trial support, drug discovery, and data platform access — has involved work with Takeda on lysosomal storage disorders including Fabry, Gaucher, and Hunter syndrome; Pfizer on the discovery and validation of genetic targets for neurodegenerative diseases; and Evotec on drug discovery that has advanced to a promising preclinical candidate for neuronopathic Gaucher disease. As pharmaceutical companies pursue increasingly targeted therapies for rare disease populations that are small and geographically dispersed, the strategic value of large curated genomic repositories has grown accordingly.

A Seven-Year Partnership Becomes a Direct Presence

The week’s opening did not represent CENTOGENE’s entry into Taiwan from a standing start. Taiwan precision medicine company BioCheck Precision Medical Lab, a subsidiary of Baoji Enterprise, distributed CENTOGENE’s testing services in Taiwan for seven years before this week’s office launch, having signed a formal distribution agreement in 2017.

“At that time, clinical genetic testing services in Taiwan were still very sparse,” said Juanita Chuang, General Manager of BioCheck, at the ceremony. The distributor-to-direct-operations transition mirrors a broader pattern in how international diagnostics companies now approach the Asia-Pacific market — moving from arms-length partnerships toward dedicated regional infrastructure as demand scales.

Chuang also recalled CENTOGENE’s role during the COVID-19 pandemic, when the company operated large-scale testing infrastructure at German airports — an episode that highlighted how molecular diagnostics infrastructure originally built for rare disease and genomic medicine was rapidly repurposed into pandemic response systems, accelerating global investment in sequencing, logistics, and laboratory scalability.

The opening ceremony included an announcement that CENTOGENE would provide CentoXome whole exome sequencing tests through the Taiwan Foundation for Rare Disorders as a direct support initiative for Taiwan’s rare disease community, alongside a discounted WGS offering for rare disease families.

Ruth Kuan-Ju Chen (left), CEO of the Taiwan Foundation for Rare Disorders, presents a certificate of appreciation to Andy Chang, CEO of CENTOGENE APAC, joined by Emily Liang, General Manager of CENTOGENE Northeast Asia and Taiwan, at the company’s Asia-Pacific headquarters opening ceremony in Taoyuan, Taiwan, May 22, 2026.

Expanding Scope: Oncology and Reproductive Medicine

Rare disease diagnostics remain CENTOGENE’s primary focus, but Andy Chang stated that the company would expand its Asia-Pacific mandate into oncology genomics and reproductive medicine — two areas where regional demand is also accelerating. Non-invasive prenatal testing has seen some of the fastest adoption of any genomic technology in Asia over the past decade, while oncology genomic profiling is increasingly embedded in clinical guidelines in Japan, South Korea, and Taiwan, albeit with inconsistent reimbursement coverage across the region.

The company indicated existing operations in India and recent branches in Taiwan and Japan, with further expansion planned across Southeast Asia, Australia, and New Zealand.

A Broader Signal for Precision Medicine in Asia

CENTOGENE’s Taiwan launch ultimately reflects several converging trends reshaping precision medicine across the region: increasing localization of genomic infrastructure, expansion of rare disease testing networks, growing demand for integrated bioinformatics platforms, and the rising strategic importance of real-world genomic datasets in drug development.

It also highlights how rare disease diagnostics are increasingly being treated not as isolated laboratory services, but as part of a broader healthcare infrastructure challenge involving data integration, patient access, regional partnerships, and translational medicine.

“Precision testing is not just a technology,” Chang said. “It can help patients and their families find answers more quickly and understand what the next step should be.”

For the families that sit at the center of that question — many of whom have spent years navigating a system not built to recognize their conditions — the distance between a headquarters in Rostock and a laboratory in Taoyuan now measures something more than geography.

Clinicians, patient advocates, laboratory partners, and industry stakeholders gather at CENTOGENE’s Asia-Pacific opening ceremony in Taiwan, May 22, 2026. Front right, rare disease ambassador and singer Wei Yi-qun, who performed at the event, represents the patient community the expansion aims to serve. Image: GeneOnline

Author

Bernice Lottering